Maa: Kanada
Kieli: englanti
Lähde: Health Canada
CAPTOPRIL
APOTEX INC
C09AA01
CAPTOPRIL
25MG
TABLET
CAPTOPRIL 25MG
ORAL
100/1000
Prescription
ANGIOTENSIN-CONVERTING ENZYME INHIBITORS
Active ingredient group (AIG) number: 0114954001; AHFS:
MARKETED
1990-12-31
0 PRODUCT MONOGRAPH PR APO-CAPTO CAPTOPRIL TABLETS USP 6.25, 12.5, 25, 50 AND 100 MG ANGIOTENSIN-CONVERTING ENZYME INHIBITOR APOTEX INC. DATE OF REVISION: 150 SIGNET DRIVE November 1, 2013 WESTON, ONTARIO M9L 1T9 CONTROL NO. 167102 1 PRODUCT MONOGRAPH APO-CAPTO Captopril Tablets USP 6.25, 12.5, 25, 50 and 100 mg THERAPEUTIC CLASSIFICATION Angiotensin-Converting Enzyme Inhibitor ACTIONS AND CLINICAL PHARMACOLOGY Captopril is an angiotensin converting enzyme inhibitor which is used in the treatment of hypertension and heart failure. The mechanism of action of captopril has not yet been fully elucidated. It appears to lower blood pressure and be an adjunct in the therapy of congestive heart failure primarily through suppression of the renin-angiotensin-aldosterone system; however, there is no consistent correlation between renin levels and response to the drug. Renin, an enzyme synthesized by the kidneys, is released into the circulation where it acts on a plasma globulin substrate to produce angiotensin I, a relatively inactive decapeptide. Angiotensin I is then converted by angiotensin converting enzyme (ACE) to angiotensin II, a potent endogenous vasoconstrictor substance. Angiotensin II also stimulates aldosterone secretion from the adrenal cortex, thereby contributing to sodium and fluid retention. Captopril prevents the conversion of angiotensin I to angiotensin II by inhibition of ACE, a peptidyldipeptide carboxy hydrolase. ACE is identical to ‘bradykininase’, and captopril may also interfere with the degradation of the vasodepressor peptide, bradykinin. However, the effectiveness of captopril in therapeutic doses appears to be unrelated to potentiation of the actions of bradykinin. Increased concentrations of bradykinin or prostaglandin E 2 may also have a role in the therapeutic effect of captopril, especially in low-renin hypertension. Inhibition of ACE results in decreased plasma angiotensin II and increased plasma renin activity (PRA), the latter resulting from loss of negative feedback on renin rele Lue koko asiakirja